Clinical Pre-screening Protocol for Ovarian Cancer

NCT03877796 · tracked via the Priya Life Science UK tracker

Sponsor

Allarity Therapeutics

Phase

Observational

Started

2019-04-11

Last updated

2026-07-30

Condition(s) studied

Ovarian Cancer

Investigational drug(s) / intervention(s)

Drug Response Predictor® (DRP)

Drug Response Predictor® (DRP): A DRP is an assay that based on samples from a tumor can predict whether the tumor will respond to a specific drug or not.

Study summary

The patient's local archival tumor tissue (FFPE) from original tumor, or from the metastatic tissue, will be collected to potentially identify if they - at a later stage of their disease - will be likely to benefit from treatment with any of the investigational cancer drugs available to Allarity Therapeutics. Data from this study can further be used to explore in a retrospective fashion, sensitivity to other chemotherapeutic drugs previously used in the treatment of their ovarian cancer, to investigate whether or not the DRP® method can predict and confirm the obtained sensitivity to the prior given drugs as well as prospective analyses guiding the Investigators on future treatments.

Eligibility

Sex

FEMALE

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Patients with histological confirmed epithelia ovarian cancer * Patients must have platinum-resistant disease, defined as progression within 6 months after the last dose of platinum-based chemotherapy, or are platinum ineligible. * Patients have received no more than one prior line of therapy in the platinum resistant or platinum ineligible setting * FFPE tumor tissue available Exclusion Criteria: * Patients who have platinum-refractory disease, defined as progression during the last platinum-based chemotherapy. * Other malignancy with exception of any stage I and II cancer that is deemed cured by the Investigator

Primary outcome measure(s)

Identification of ovarian cancer patients with high likelihood of being sensitive to investigational cancer drug — up to 2 years
based on FFPE ovarian cancer tissue

Trial sites (9)

Facility	City	Region	Status
Moffitt Cancer Center	Tampa	Florida	Recruiting
Emory Winship Cancer Institute	Atlanta	Georgia	Recruiting
University of New Mexico Comprehensive Cancer	Albuquerque	New Mexico	Recruiting
The Blavatnik Family-Chelsea Medical Center at Mount Sinai	New York	New York	Recruiting
OU Health Stephenson Cancer Center	Oklahoma City	Oklahoma	Recruiting
University Medical Center Cancer Center	Lubbock	Texas	Recruiting
Swedish Center for Research and Innovation	Seattle	Washington	Recruiting
Beatson West of Scotland Cancer Centre	Glasgow	Scotland	Recruiting
Guy's and St Thomas' NHS Foundation Trust, Guy's Hospital	London	United Kingdom	Recruiting

Other trials for the same condition

First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine Recruiting

A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors Active, not recruiting

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Recruiting

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression Recruiting

Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65). Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03877796 on ClinicalTrials.gov ↗ ← All trials in the UK